Cello operates within a $30bn healthcare outsourced advisory market supported by 5% annual R&D growth. This market is defensive and growing. In many respects the challenge is less about finding work but securing the staff to complete it. Consequently, management has over the past few years focused on hiring, training and retaining talent and the benefits are now coming through. H1 net fees were up +6.8% and adjusted operating profit +12.3%. With PE actively acquiring in this sector and in
24 Sep 2019
Cello Health - Growing in a consolidating sector

